Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.40 |
| ▸ | NPY1R | P25929 | 9/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9488991 | 0.90 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL2481089 | 0.90 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL27325461 | 0.88 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| Hydrochloric Acid SCHEMBL27645702 | 0.87 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL2347308 | 0.86 | ITGB3 (0.36) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL61231 | 0.84 | FOLH1 (0.39) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL1263209 | 0.84 | FOLH1 (0.39) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL2483025 | 0.84 | C3AR1 (0.34) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL9924206 | 0.84 | C3AR1 (0.34) | NPY4RNPY1RNPY5RNPY2RITGB3 | |
| SCHEMBL144726 | 0.84 | GGT1 (0.40) | NPY4RNPY1RNPY5RNPY2RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | NPY4R 1297/4885NPY1R 599/4885NPY5R 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.